Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis

Trial Profile

Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Sodium cromoglicate (Primary) ; Sodium cromoglicate
  • Indications Systemic mastocytosis
  • Focus Therapeutic Use
  • Sponsors Patara Pharma
  • Most Recent Events

    • 27 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 09 Aug 2016 This trial was completed in Germany (End Date: 22 Jul 2016).
    • 15 Jun 2016 The trial was completed in Spain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top